Welcome to our dedicated page for Sol-Gel Technologies Ltd. Ordinary Shares news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol-Gel Technologies Ltd. Ordinary Shares stock.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative topical dermatological drug products. The company's core focus is on utilizing its proprietary microencapsulation delivery system, which leverages silica-based microcapsules to enhance the efficacy and tolerability of dermatological treatments. This technology creates a protective barrier around drug substances, controlling the release rate and reducing side effects. Sol-Gel's lead product candidates, Vered for papulopustular rosacea and Twin and Sirs-T for acne vulgaris, are prime examples of this advanced delivery system in action.
Sol-Gel has achieved significant milestones in its product pipeline. The company has received FDA approval for two major dermatology products: TWYNEO® and EPSOLAY®. TWYNEO, which combines tretinoin and benzoyl peroxide, is designed for the topical treatment of acne vulgaris. EPSOLAY, which contains encapsulated benzoyl peroxide, addresses inflammatory lesions of rosacea. Both products are commercialized in the U.S. by Galderma.
A key highlight of Sol-Gel's innovative approach is SGT-610, a hedgehog signaling pathway blocker in development for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome. This candidate, which has received Orphan Drug and Breakthrough Therapy designations from the FDA, is currently undergoing pivotal Phase 3 testing. If approved, SGT-610 could become the first treatment specifically for Gorlin syndrome, a genetic disorder that predisposes individuals to developing BCC.
Financially, Sol-Gel reported a revenue of $0.2 million for the third quarter of 2023, primarily from licensing agreements. The company incurred research and development expenses of $4.7 million and general and administrative expenses of $1.9 million in the same quarter. Despite a net loss of $5.7 million, Sol-Gel maintains a robust financial position with $26.1 million in cash, cash equivalents, and deposits, and $17.2 million in marketable securities as of September 30, 2023. This financial stability is expected to support the company's operations and capital expenditure requirements into the second half of 2025.
Sol-Gel's commitment to addressing unmet needs in dermatology extends beyond its own products. The company is actively engaged in discussions with potential partners to secure new international licenses for its marketed products. This strategy aims to generate non-dilutive capital and expand the global reach of its innovative dermatological treatments.
For more detailed information, please visit www.sol-gel.com.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announces the commercial launch of TWYNEO in Spring 2022, a groundbreaking 2-in-1 topical cream combining tretinoin and benzoyl peroxide, specifically designed to treat moderate-to-severe acne.
Galderma, Sol-Gel’s U.S. commercialization partner, will promote TWYNEO at the AAD Annual Meeting from March 25-29, 2022, in Boston. TWYNEO utilizes patented microencapsulation technology for effective and timely delivery. CEO Alon Seri-Levy highlights the significance of this product for both patients and investors.
Sol-Gel Technologies (Nasdaq: SLGL) announced its participation in two virtual conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect 2022 Healthcare Conference, with a corporate presentation webcast available from January 10-13, 2022. The company focuses on developing topical drug products for skin diseases, leveraging its microencapsulation technology. The FDA is set to conduct a pre-approval inspection for its product EPSOLAY in February 2022, aiming for commercialization with Galderma.
Sol-Gel Technologies (NASDAQ: SLGL) announced that the FDA intends to conduct a pre-approval inspection of the production site for its drug EPSOLAY during the week of February 14, 2022. EPSOLAY is under FDA review for treating inflammatory lesions of rosacea in adults. CEO Alon Seri Levy expressed optimism about this development, as previous inspection timelines had been delayed due to COVID-19. The drug's technology involves encapsulating benzoyl peroxide in microcapsules for gradual release, supported by patents until 2040.
Sol-Gel Technologies (SLGL) reported a profitable third quarter with total revenues of $8.8 million, net income of $1.3 million, and an EPS of $0.06. Key revenue drivers included a $3.5 million milestone payment from Galderma linked to FDA approval of TWYNEO® and a $4.0 million upfront payment. Sol-Gel secured a new agreement with Padagis that will yield $21 million over 24 months, allowing them to focus on development. Their cash runway extends through 2023, bolstered by partnerships and sales of generics.
Sol-Gel Technologies (Nasdaq: SLGL) announced its participation in the Jefferies London Healthcare Conference on November 16-17, 2021. Dr. Alon Seri-Levy, CEO, will present live on November 16 from 8:00 to 8:35 AM GMT. The presentation will discuss Sol-Gel’s focus on developing treatments for skin diseases, including the FDA-approved TWYNEO for acne and EPSOLAY, which is pending FDA action. The company is also advancing early-stage candidates targeting other dermatologic conditions.
For more details, visit www.sol-gel.com.
Sol-Gel Technologies (Nasdaq: SLGL) announced a new agreement with Padagis, securing $21 million over 24 months by transferring rights to two marketed generic drugs and eight unapproved generic programs. The company will retain collaboration rights for two valuable generic programs. This agreement is expected to extend Sol-Gel's cash runway through at least Q4 2023. Sol-Gel focuses on advancing its innovative pipeline and supporting Galderma in launching TWYNEO and EPSOLAY, pending FDA approvals.
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) has announced its participation in the virtual Cantor Global Healthcare Conference from September 27-30, 2021. During this event, Dr. Alon Seri-Levy and CFO Gilad Mamlok will engage in a fireside chat discussion on September 30, starting at 10:40 a.m. ET. The discussion will be available on demand, and a replay can be accessed for 30 days. Sol-Gel focuses on developing topical dermatology treatments, leveraging proprietary technologies for products like TWYNEO and EPSOLAY. For more information, visit their official website.
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) announced its participation in H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-15, 2021. The event will feature an on-demand presentation and one-on-one meetings with Chief Financial Officer Gilad Mamlok. The presentation becomes available on September 13 at 7 a.m. ET. Sol-Gel specializes in developing topical drug products for skin diseases, including FDA-approved TWYNEO for acne treatment. Their pipeline includes EPSOLAY for rosacea, with a pending NDA, as well as candidates SGT-210, SGT-310, and SGT-510 for various skin conditions.
Sol-Gel Technologies (NASDAQ: SLGL) announced FDA approval of TWYNEO® for acne treatment, triggering an $8 million milestone payment from Galderma. The company signed exclusive licensing agreements for TWYNEO® and EPSOLAY®, which is pending FDA action. Second quarter 2021 revenue was $0.9 million, down from $1.1 million in 2020. Research and development costs increased to $6.9 million, while general and administrative costs decreased to $2.0 million. The company reported a net loss of $8.0 million for the quarter and has $38.9 million in cash and securities to fund operations through early 2023.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announced FDA approval for TWYNEO, a once-daily cream for acne vulgaris, combining tretinoin and benzoyl peroxide. This marks the first FDA-approved fixed-dose combination for this treatment, utilizing proprietary microencapsulation technology. TWYNEO is patent protected until 2038. Sol-Gel is set to receive a regulatory milestone payment from Galderma, its U.S. commercialization partner, and retains an option for commercialization rights after five years. The drug is expected to significantly impact the treatment landscape for acne patients.
FAQ
What is the current stock price of Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)?
What is the market cap of Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)?
What is Sol-Gel Technologies Ltd.?
What are Sol-Gel's lead product candidates?
What is unique about Sol-Gel's microencapsulation technology?
Which products of Sol-Gel are FDA approved?
What is SGT-610?
What financial position does Sol-Gel hold?
Who commercializes Sol-Gel's approved products in the U.S.?
What are the recent financial results of Sol-Gel?
How does Sol-Gel plan to expand its reach?
Where can more information about Sol-Gel Technologies be found?
